Short‐Term, Low‐Dose Spironolactone for Treatment of Hyperandrogenic Symptoms of Polycystic Ovary Syndrome—A Systematic Review
Clinical Endocrinology · 2026-03 · 104 (3) · 179-187
DOI: 10.1111/cen.70062 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Endocrinology, online erschienen am 24.11.2025. Verfasst von Telma Martins Viveiros und 6 weiteren Autor:innen. Beteiligte Einrichtung: UCL Medical School, Faculty of Medical Sciences, University College London, London, UK. Hauptthemen laut MEDLINE: Spironolactone, Polycystic Ovary Syndrome, Hyperandrogenism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
Polycystic ovary syndrome (PCOS) is a common condition, that manifests as menstrual irregularities, subfertility, or symptoms of hyperandrogenism – including hirsutism, adult acne, and alopecia. Current pharmacological treatment of the hyperandrogenic symptoms includes the combined oral contraceptive pill. However, there are multiple contraindications and side‐effects, which limit their use. Anti‐androgens, such as spironolactone, are commonly prescribed off‐label but its efficacy in PCOS is uncertain. This review aims to evaluate the efficacy and safety of spironolactone, when compared to other nonhormonal medications in the management of PCOS hyperandrogenic symptoms.
Methods
Comprehensive literature searches were conducted across MEDLINE, EMBASES, PUBMED and SCOPUS. RCTs published in English assessing the use of spironolactone for hyperandrogenism in PCOS were included. The quality of papers was assessed using Cochrane RoB 2.0 tool. Meta‐analysis was conducted using a random‐effects model, reporting as standardised mean differences and 95% confidence intervals.
Results
Of 3378 studies identified, five open‐label RCTs met the inclusion criteria, three of which were included in the meta‐analysis. Spironolactone, monotherapy or combination with metformin, showed no statistically significant difference in reducing Ferriman‐Gallwey scores, total testosterone levels or BMI compared to metformin monotherapy. Side effects of spironolactone included menstrual irregularities, polyuria, and gastrointestinal symptoms.
Conclusion
Current evidence does not show any significant difference in the use of spironolactone when compared to metformin. Given its widespread use and limited safety concerns, spironolactone remains an off‐label option, especially for those unable to take hormonal contraceptives. However, larger, better quality studies are needed to establish its efficacy in PCOS management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL Medical School, Faculty of Medical Sciences, University College London, London, UK.
- Reproductive Medicine Unit, University College London Hospital, London, UK.
- Institute for Women's Health, University College London, London, UK.
- Beginnings Assisted Conception Unit, Epsom and St Helier University Hospitals, London, UK.
ORCID-Profile: Telma Martins Viveiros
Zitieren
APA
Viveiros, T. M., Deshpande, N., Karderinis, I., Ma, Y., Clarke, S., Talaulikar, V., & Wattar, B. (2026). Short‐Term, Low‐Dose Spironolactone for Treatment of Hyperandrogenic Symptoms of Polycystic Ovary Syndrome—A Systematic Review. Clinical Endocrinology, 104(3), 179-187. https://doi.org/10.1111/cen.70062
Vancouver
Viveiros TM, Deshpande N, Karderinis I, Ma Y, Clarke S, Talaulikar V, et al. Short‐Term, Low‐Dose Spironolactone for Treatment of Hyperandrogenic Symptoms of Polycystic Ovary Syndrome—A Systematic Review. Clinical Endocrinology. 2026;104(3):179-187. doi:10.1111/cen.70062
BibTeX
@article{Viveiros2026,
author = {Viveiros, Telma Martins and Deshpande, Neha and Karderinis, Irene and Ma, Yangxinrui and Clarke, Sophie and Talaulikar, Vikram and Wattar, Bassel},
title = {Short‐Term, Low‐Dose Spironolactone for Treatment of Hyperandrogenic Symptoms of Polycystic Ovary Syndrome—A Systematic Review},
journal = {Clinical Endocrinology},
year = {2026},
volume = {104},
number = {3},
pages = {179--187},
doi = {10.1111/cen.70062}
}
EUVIMED